Initially, in 2012, the USPSTF recommended against prostate-specific antigen (PSA)-based screening for prostate cancer in all men, citing concerns about overdiagnosis and overtreatment, which could lead to significant harms such as erectile dysfunction and urinary incontinence [5,6]. The gene discussed is KLK3; the disease is Urinary incontinence.